April 30, 2025

Myelin Proteins Altered After Splice Inhibition, Study

Inhibiting a protein called hnRNP A1 disrupted myelin repair in mouse brains without causing noticeable behavioral changes, according to a new study exploring its effects across multiple brain regions.

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 17, 2025

We Want Your Perspective!

Join our roster of respected specialists and share your clinical perspectives.

Conexiant

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 15, 2025

CT Exam Cancer Risk: Over 100,000 Cases Per Year

"At current utilization and radiation dose levels, CT examinations in 2023 were projected to result in approximately 103,000 future cancers," warns a new study that could reshape imaging practices.

Conexiant

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

July 26, 2024

EHR Use Disparities: Female vs. Male Surgeons

A recent study published in JAMA Network Open reveals gender differences in electronic health record (EHR) usage among surgeons, with female surgeons writing significantly longer progress notes than their male counterparts.

Conexiant

August 07, 2024

FDA Approves Voranigo for Grade 2 IDH-Mutant Glioma

The FDA's approval of voranigo marks a significant milestone as it becomes the first drug approved in the U.S. for the treatment of Grade 2 IDH-mutant glioma, a type of brain tumor, with promising results in a late-stage clinical trial.

Reuters

September 03, 2024

Mobile Phones Not Linked to Brain Cancer

WHO and global health bodies called for re-evaluation of the 2011 cancer risk classification.

Reuters